Cognition Therapeutics, Inc. (CGTX) — Stock Score Summary

Cognition Therapeutics, Inc. (CGTX) has a MoatMap StockRank of 4/100 based on Quality (29/100), Value (35/100), and Momentum (14/100) factor scores. The current signal is STRONG SELL. Cognition Therapeutics is a micro-cap clinical-stage biopharmaceutical company. It carries extremely high binary trial risk and lacks structural moats or cash flow.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting age-related degenerative diseases of the central nervous system and retina. Its proprietary discovery platform has identified candidates like elayta (CT1812), which targets the sigma-2 receptor complex to protect synapses from toxic oligomers. The company occupies a specialized niche in neurodegenerative research, focusing on disease-modifying mechanisms for Alzheimer's and dry AMD.

Key Financial Metrics

Price$1.15
Market Cap$107M
P/E (Forward)-4.92
Price/Book3.53
Return on Invested Capital-68.1%
Debt/Equity1.86
Gross Margin0.0%
Operating Margin0.0%

Cognition Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Cognition Therapeutics, Inc.’s (CGTX) StockRank?
MoatMap’s StockRank for Cognition Therapeutics, Inc. (CGTX) is 4/100, with a Strong Sell signal. It is a composite of Quality (29), Value (35), and Momentum (14) factor ranks across MoatMap’s 19,000+ stock universe.
Does Cognition Therapeutics, Inc. have an economic moat?
Cognition Therapeutics, Inc. (CGTX) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Cognition Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Cognition Therapeutics, Inc. (CGTX) is Strong Sell, based on a StockRank of 4/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Cognition Therapeutics, Inc. in?
Cognition Therapeutics, Inc. (CGTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksCGTX deep dive reportAI ChampionsHow we score stocksSense-check another stock